FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093129968> ?p ?o ?g. }

• W3093129968 endingPage "10278" @default.
• W3093129968 startingPage "10271" @default.
• W3093129968 abstract "Several progresses have been achieved for first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with Gem-NabP and FOLFIRINOX extensively used as standard first line regimens. However, the best second-line chemotherapy choice after progression is still not completely defined. The aim of this study is to compare effectiveness and safety of two possible second-line therapeutic options, FOLFOX and FOLFIRI, after progression to Gem-NabP.From January 2015 to December 2018, patients with metastatic PDAC, progressed to the first-line treatment with Gem-NabP, and treated with a fluoropyrimidine-based second-line chemotherapy were considered eligible for our retrospective analysis. Overall survival (OS) and progression free survival (PFS) were set as primary endpoints whereas, disease control rate (DCR) and the rate and severity of treatment-related AEs were secondary endpoints.Overall, 31 patients were treated with Gem-NabP in first-line regimen, 11 received second-line with FOLFOX and 20 with FOLFIRI after progression. Baseline demographic and clinic features were similar in the two groups excluding median age of 55.5 years (range: 50-73) and 68 years (range: 59-72) in FOLFIRI and FOLFOX groups, respectively (p=0.002). Median PFS was three months (95%CI: 3-4), with no significative difference between the two groups. Median OS was eight months (95%CI: 5-10) and was significantly higher in the FOLFIRI group compared with the FOLFOX group, nine months (95%CI: 7-17) vs five months (95%CI: 2-10; p<0.01). The most commonly reported adverse events were grade 1 or 2 with anemia most frequent in the FOLFOX group (36.4% vs 10.0%) and diarrhea in the FOLFIRI group (40.0% vs 9.1%). Grade 3-4 adverse events as neutropenia, diarrhea and nausea/vomiting, occurred in 10 patients (32.2%) without differences between the two groups.Our results seem to support the use of fluoropyrimidine-based second-line therapy for patients with metastatic pancreatic cancer, confirming the effectiveness and safety, to a greater extent with FOLFIRI regimen, after progression to the Gem-NabP." @default.
• W3093129968 created "2020-10-22" @default.
• W3093129968 creator A5004066283 @default.
• W3093129968 creator A5004699983 @default.
• W3093129968 creator A5009629939 @default.
• W3093129968 creator A5037756908 @default.
• W3093129968 creator A5047413929 @default.
• W3093129968 date "2020-10-01" @default.
• W3093129968 modified "2023-09-27" @default.
• W3093129968 title "<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>" @default.
• W3093129968 cites W2019607817 @default.
• W3093129968 cites W2023335214 @default.
• W3093129968 cites W2063856853 @default.
• W3093129968 cites W2064906202 @default.
• W3093129968 cites W2098342562 @default.
• W3093129968 cites W2151253787 @default.
• W3093129968 cites W2156714215 @default.
• W3093129968 cites W2164286021 @default.
• W3093129968 cites W2165480504 @default.
• W3093129968 cites W2187917981 @default.
• W3093129968 cites W2230554281 @default.
• W3093129968 cites W2415398754 @default.
• W3093129968 cites W2472707660 @default.
• W3093129968 cites W2590683350 @default.
• W3093129968 cites W2749989634 @default.
• W3093129968 cites W2885738414 @default.
• W3093129968 cites W2907628700 @default.
• W3093129968 cites W2922042574 @default.
• W3093129968 cites W2980161304 @default.
• W3093129968 doi "https://doi.org/10.2147/cmar.s267393" @default.
• W3093129968 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7585276" @default.
• W3093129968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33116881" @default.
• W3093129968 hasPublicationYear "2020" @default.
• W3093129968 type Work @default.
• W3093129968 sameAs 3093129968 @default.
• W3093129968 citedByCount "6" @default.
• W3093129968 countsByYear W30931299682021 @default.
• W3093129968 countsByYear W30931299682022 @default.
• W3093129968 countsByYear W30931299682023 @default.
• W3093129968 crossrefType "journal-article" @default.
• W3093129968 hasAuthorship W3093129968A5004066283 @default.
• W3093129968 hasAuthorship W3093129968A5004699983 @default.
• W3093129968 hasAuthorship W3093129968A5009629939 @default.
• W3093129968 hasAuthorship W3093129968A5037756908 @default.
• W3093129968 hasAuthorship W3093129968A5047413929 @default.
• W3093129968 hasBestOaLocation W30931299681 @default.
• W3093129968 hasConcept C121608353 @default.
• W3093129968 hasConcept C126322002 @default.
• W3093129968 hasConcept C143998085 @default.
• W3093129968 hasConcept C168563851 @default.
• W3093129968 hasConcept C203092338 @default.
• W3093129968 hasConcept C2776694085 @default.
• W3093129968 hasConcept C2776705615 @default.
• W3093129968 hasConcept C2777148230 @default.
• W3093129968 hasConcept C2778260052 @default.
• W3093129968 hasConcept C2780210213 @default.
• W3093129968 hasConcept C2780258809 @default.
• W3093129968 hasConcept C2780259306 @default.
• W3093129968 hasConcept C2780739268 @default.
• W3093129968 hasConcept C2780962732 @default.
• W3093129968 hasConcept C2781413609 @default.
• W3093129968 hasConcept C526805850 @default.
• W3093129968 hasConcept C71924100 @default.
• W3093129968 hasConceptScore W3093129968C121608353 @default.
• W3093129968 hasConceptScore W3093129968C126322002 @default.
• W3093129968 hasConceptScore W3093129968C143998085 @default.
• W3093129968 hasConceptScore W3093129968C168563851 @default.
• W3093129968 hasConceptScore W3093129968C203092338 @default.
• W3093129968 hasConceptScore W3093129968C2776694085 @default.
• W3093129968 hasConceptScore W3093129968C2776705615 @default.
• W3093129968 hasConceptScore W3093129968C2777148230 @default.
• W3093129968 hasConceptScore W3093129968C2778260052 @default.
• W3093129968 hasConceptScore W3093129968C2780210213 @default.
• W3093129968 hasConceptScore W3093129968C2780258809 @default.
• W3093129968 hasConceptScore W3093129968C2780259306 @default.
• W3093129968 hasConceptScore W3093129968C2780739268 @default.
• W3093129968 hasConceptScore W3093129968C2780962732 @default.
• W3093129968 hasConceptScore W3093129968C2781413609 @default.
• W3093129968 hasConceptScore W3093129968C526805850 @default.
• W3093129968 hasConceptScore W3093129968C71924100 @default.
• W3093129968 hasLocation W30931299681 @default.
• W3093129968 hasLocation W30931299682 @default.
• W3093129968 hasLocation W30931299683 @default.
• W3093129968 hasOpenAccess W3093129968 @default.
• W3093129968 hasPrimaryLocation W30931299681 @default.
• W3093129968 hasRelatedWork W1999397682 @default.
• W3093129968 hasRelatedWork W2417717847 @default.
• W3093129968 hasRelatedWork W2599910524 @default.
• W3093129968 hasRelatedWork W2738360744 @default.
• W3093129968 hasRelatedWork W2910998150 @default.
• W3093129968 hasRelatedWork W2954666840 @default.
• W3093129968 hasRelatedWork W3000742518 @default.
• W3093129968 hasRelatedWork W3083620303 @default.
• W3093129968 hasRelatedWork W3201057321 @default.
• W3093129968 hasRelatedWork W4382806805 @default.
• W3093129968 hasVolume "Volume 12" @default.
• W3093129968 isParatext "false" @default.
• W3093129968 isRetracted "false" @default.

• next